In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Chimerix (NASDAQ: CMRX), with a price target of $10. The company’s shares opened today at $4.51.
According to TipRanks.com, White is a 5-star analyst with an average return of 26.1% and a 55.7% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
Currently, the analyst consensus on Chimerix is a Moderate Buy with an average price target of $8.
See today’s analyst top recommended stocks >>
Based on Chimerix’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $19.83 million. In comparison, last year the company had a GAAP net loss of $16.68 million.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Michelle Berrey, the President & CEO of CMRX bought 11,250 shares for a total of $47,925.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox.
